Solved Case Analysis: The Aleve Launch A by Mark E. Parry, Katie Fehskens


Get the Best Analysis to this Case Study written by MBA/CFA writers.

**Solution would be delivered to your registered email address within next 4 days. If you want the solution any earlier drop an email at  Click Here to see how it works



In 1988, Syntex formed a joint venture with Procter & Gamble to market naproxen sodium, a prescription pain reliever sold by Syntex under the names Anaprox and Naprosyn, in the over-the-counter (OTC) internal analgesics market. The product received DFA approval for sale over the counter in January 1994, and was to be launched in June 1994 under the brand name Aleve. This was not Procter & Gamble’s first foray into marketing OTC pain relievers. In the 1980s, P&G attempted to launch Encaprin, a coated aspirin product. Encaprin was unable to compete with the ibuprofen products entering the market, and the product was eventually pulled. Syntex and P&G know that they were entering into a highly competitive, if not voracious, market. How could they build on the success of the prescription product? How could they introduce a new pain reliever in an overcrowded OTC market? How much would they have to spend to gain significant market share?

Publishing Authority:

Darden Business Publishing – University of Virginia


There are no reviews yet.

Be the first to review “Solved Case Analysis: The Aleve Launch A by Mark E. Parry, Katie Fehskens”

Your email address will not be published. Required fields are marked *